Taysha Gene Therapies (NASDAQ:TSHA) Upgraded by Truist Financial to “Strong-Buy” Rating

Taysha Gene Therapies (NASDAQ:TSHA) was upgraded by equities researchers at Truist Financial to a “strong-buy” rating in a research report issued to clients and investors on Wednesday,Zacks.com reports.

TSHA has been the subject of several other research reports. The Goldman Sachs Group set a $11.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, December 4th. Weiss Ratings restated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research note on Monday, December 29th. Raymond James Financial reaffirmed a “strong-buy” rating and issued a $13.00 price objective on shares of Taysha Gene Therapies in a report on Tuesday, January 6th. Wells Fargo & Company lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, January 5th. Finally, Needham & Company LLC boosted their target price on shares of Taysha Gene Therapies from $10.00 to $12.00 and gave the company a “buy” rating in a report on Thursday, March 19th. Two equities research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Taysha Gene Therapies currently has a consensus rating of “Buy” and an average target price of $11.09.

Taysha Gene Therapies Stock Up 10.9%

TSHA stock opened at $4.58 on Wednesday. The stock has a fifty day moving average of $4.60 and a 200-day moving average of $4.58. Taysha Gene Therapies has a fifty-two week low of $1.05 and a fifty-two week high of $6.02. The company has a market capitalization of $1.32 billion, a price-to-earnings ratio of -13.47 and a beta of 1.02. The company has a debt-to-equity ratio of 0.20, a quick ratio of 12.23 and a current ratio of 12.23.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Thursday, March 19th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.11) by $0.03. The business had revenue of $5.49 million for the quarter, compared to analysts’ expectations of $1.89 million. Taysha Gene Therapies had a negative return on equity of 56.64% and a negative net margin of 1,144.97%. As a group, equities research analysts predict that Taysha Gene Therapies will post -0.35 earnings per share for the current year.

Insider Activity

In related news, CFO Kamran Alam sold 78,968 shares of the business’s stock in a transaction that occurred on Friday, January 23rd. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00. Following the completion of the transaction, the chief financial officer owned 1,467,635 shares of the company’s stock, valued at approximately $6,971,266.25. The trade was a 5.11% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Sean P. Nolan sold 136,789 shares of the stock in a transaction that occurred on Friday, January 23rd. The stock was sold at an average price of $4.75, for a total transaction of $649,747.75. Following the completion of the sale, the chief executive officer owned 2,949,569 shares in the company, valued at $14,010,452.75. This represents a 4.43% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders sold 598,623 shares of company stock worth $2,822,188. 3.78% of the stock is owned by company insiders.

Institutional Investors Weigh In On Taysha Gene Therapies

Several large investors have recently added to or reduced their stakes in TSHA. AQR Capital Management LLC increased its stake in Taysha Gene Therapies by 325.6% in the 1st quarter. AQR Capital Management LLC now owns 107,899 shares of the company’s stock worth $150,000 after acquiring an additional 82,545 shares during the last quarter. Geode Capital Management LLC grew its holdings in shares of Taysha Gene Therapies by 3.5% during the second quarter. Geode Capital Management LLC now owns 3,793,572 shares of the company’s stock worth $8,765,000 after purchasing an additional 128,840 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Taysha Gene Therapies by 13.5% during the second quarter. Rhumbline Advisers now owns 233,256 shares of the company’s stock worth $539,000 after purchasing an additional 27,794 shares in the last quarter. Prudential Financial Inc. increased its position in shares of Taysha Gene Therapies by 50.5% in the second quarter. Prudential Financial Inc. now owns 22,790 shares of the company’s stock worth $53,000 after purchasing an additional 7,650 shares during the last quarter. Finally, XTX Topco Ltd raised its stake in Taysha Gene Therapies by 57.9% in the second quarter. XTX Topco Ltd now owns 320,737 shares of the company’s stock valued at $741,000 after purchasing an additional 117,608 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.